Overview

Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)

Status:
Completed
Trial end date:
2018-04-03
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate the efficacy of mesalamine for the induction of clinical and endoscopic remission in subjects with active, mild to moderate UC. Subject will receive 4 g extended release granules (sachet) once daily.
Phase:
Phase 3
Details
Lead Sponsor:
Ferring Pharmaceuticals
Treatments:
Mesalamine